Skip to content
ViewSmartBlog UK

Administering Pluripotent Cells in Utero to Infants with Neural Tube Defect Boosts Quality of Life, Research Shows

A pioneering research effort has found that delivering regenerative cells to developing infants affected by spina bifida while undergoing fetal surgery may represent a "significant breakthrough" in treating birth defects.

Study Parameters and Security

The research conducted in the United States involved six unborn babies with myelomeningocele. Doctors administered mother's placental stem cells on the exposed area of the baby's spinal cord as part of the surgical correction.

Critically, the stem cell application proved to be secure. Doctors verified that the treatment did not lead to tumors, hinder surgical recovery, or prevent the reversal of co-occurring hindbrain herniation.

Promising Outcomes

Magnetic resonance imaging performed on the newborns confirmed a complete reversal of hindbrain herniation in each of the babies. This neurological improvement is closely linked to better mobility and function.

"If it makes more children capable of walking who wouldn't have, it may emerge as their standard of care," said the lead researcher. "The outcomes appear profoundly encouraging and create a pathway toward lots of potential novel therapies."

Long-Term Prospects and Optimism

Independent medical specialists indicated that additional validation of these noted improvements could announce a "new era" in fetal surgery. The possibility of ameliorating nerve function impairment occurring during fetal development is regarded as a paradigm-shifting aim.

Especially significant would be better management of bladder and bowel function, which are common challenges for individuals living with this defect.

Future Directions

Despite this being a first-in-human effort was small in scale, its confirmed tolerability and hopeful trends offer a robust platform for larger, more comprehensive studies. The integration of stem cell therapy with proven prenatal surgical methods presents significant potential for changing life trajectories for future generations with myelomeningocele.

About the author

Megan Shaw

A tech journalist and digital strategist with over a decade of experience covering emerging technologies and innovation across Europe.

ViewSmartBlog UK

Type to search articles.